Candel Therapeutics (CADL)Baker Bros. Advisors LP reduced its stake -545K shares

2.44M

Shares reported · -545K vs prior quarter

0.15%

Disclosed portfolio weight

$13.8M

Reported value

Holdings as of

Mar 31, 2025

Filed

May 15, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 17, 2025Insider · 2 peopleInsiders: 2 sales (~$320K)
2. Mar 18, 2025Insider · 3 peopleInsiders: 3 sales (~$905K)
3. Mar 19, 2025InsiderCEO sold ~$3.6K of CADL shares in the open market

What came next

1. Jun 30, 2025InsiderOfficer sold ~$3.9K of CADL shares in the open market
2. Jul 28, 2025InsiderOfficer sold ~$6.5K of CADL shares in the open market

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Candel Therapeutics

OQRO holds no insider, Congress, fund or contract record for Candel Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CADL page.

How this filing works

• SEC Form 13F

Other disclosures at Candel Therapeutics

• SEC Form 13F-HRMay 15, 2026
• SEC Form 4Jul 30, 2025
• SEC Form 4Jul 2, 2025
• SEC Form 4Mar 20, 2025
• SEC Form 4Mar 20, 2025
• SEC Form 4Mar 20, 2025

Everything OQRO holds on this company is on its CADL page.